Learn more →
Back to Expert Scholars
Translational Medicine / 转化医学Mesothelioma & Rare Thoracic

Raffit Hassan

拉菲特·哈桑

MD

🏢National Cancer Institute, NIH(美国国立癌症研究所)🌐USA

Senior Investigator, Thoracic and GI Malignancies Branch胸部与消化道恶性肿瘤科高级研究员

57
h-index
3
Key Papers
3
Awards
3
Key Contributions

👥Biography 个人简介

Raffit Hassan at the NCI is the world's leading authority on mesothelin-targeted cancer therapy. He discovered mesothelin as a tumor antigen and developed SS1P immunotoxin, amatuximab, and CAR-T approaches against mesothelin-expressing malignancies including mesothelioma, lung adenocarcinoma, and pancreatic cancer.

Share:

🧪Research Fields 研究领域

Mesothelioma间皮瘤
Mesothelin-Targeted Therapy间皮素靶向治疗
Immunotoxins免疫毒素

🎓Key Contributions 主要贡献

Mesothelin Biology

Characterized mesothelin as a cell surface glycoprotein overexpressed in mesothelioma and several solid tumors, establishing it as a major therapeutic target.

Immunotoxin Development

Developed SS1P (anti-mesothelin immunotoxin) and conducted first-in-human trials, demonstrating antitumor activity and paving the way for next-generation mesothelin-directed agents.

CAR-T Therapy

Pioneered mesothelin-directed CAR-T cell therapy clinical trials in solid tumors including mesothelioma, achieving early clinical responses and advancing the solid tumor CAR-T field.

Representative Works 代表性著作

[1]

Mesothelin-targeted immunotherapy of ovarian cancer and malignant mesothelioma

Current Opinion in Oncology (2010)

Comprehensive review of mesothelin biology and therapeutic targeting, establishing the scientific foundation for multiple clinical programs.

[2]

Amatuximab and pemetrexed/cisplatin in pleural mesothelioma (COMMAND trial)

Annals of Oncology (2014)

First phase II trial of anti-mesothelin antibody combined with chemotherapy, demonstrating feasibility and signals of efficacy.

[3]

Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus IV infusion

Clinical Cancer Research (2007)

Established the safety profile and early efficacy signals of mesothelin immunotoxin, enabling later combination strategies.

🏆Awards & Recognition 奖项与荣誉

🏆NIH Director's Award
🏆MARF Outstanding Mesothelioma Researcher Award
🏆American Cancer Society Research Scholar Award

📄Data Sources 数据来源

Last updated: 2026-01-15 | All information from publicly available academic sources

关注 拉菲特·哈桑 的研究动态

Follow Raffit Hassan's research updates

留下邮箱,当我们发布与 Raffit Hassan(National Cancer Institute, NIH)相关的新研究或访谈时,我们会通知你。

我们不会泄露你的信息,也不会发送无关内容。随时可以退订。

Explore More Experts

Discover the researchers shaping the future of cancer treatment